$SLXN

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 23, 2026, Silexion Therapeutics Corp (the “ Company ”) reconvened (for the second time) its extraordinary general meeting (the “ Meeting ”), which had originally been scheduled for September 9, 2026 but

Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.

Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2026 results and said its SIL204 program moved into active Phase 2/3 for locally advanced pancreatic cancer. The company received Germany’s BfArM CTA approval and initiated the trial at Tel Aviv Sourasky Medical Center in late July. It also reported preclinical immune-sensitization data and closed a public offering with about $2.5M gross proceeds. Q2 R&D was ~$2.2M and net loss ~$3.6M.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering GRAND CAYMAN, Cayman Islands, August 11, 2026 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA inter

Silexion Therapeutics (SLXN) priced a $2.5 million public offering of 3.85 million ordinary shares and Series E warrants at $0.65 per share, with warrants exercisable at $0.65 and expiring in five years. Net proceeds will fund its Phase 2/3 SIL204 trial and general purposes. SLXN fell 31% to $1.03.

Silexion Therapeutics (NASDAQ: SLXN) reported new preclinical results for its SIL204 siRNA in KRAS-mutant pancreatic and NSCLC cell lines. SIL204 increased FAS (CD95) expression and decreased HLA-G, supporting a multi-pathway immune-sensitization rationale for combining with anti-PD-(L)1 therapies. The company is advancing SIL204 in Phase 2/3 after starting a first clinical trial site at Tel Aviv Sourasky Medical Center in late July 2026.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Resignation of Director On July 30, 2026, Professor Amnon Peled notified the Board of Directors (the “ Board ”) of Sile

Tel Aviv Sourasky Medical Center and Israeli biotech Silexion Therapeutics (Nasdaq: SLXN) announced a first-in-world clinical trial of SIL204, an siRNA therapy targeting KRAS mutations in pancreatic cancer. The study will enroll about 18 patients initially to assess safety, then expand, potentially to 166. SIL204 will be injected into tumors and combined with standard systemic treatment.